11/06/2026
GLP-1s, such as Ozempic and Mounjaro, are always a hot topic, but especially so last month when concerns were raised that the rapid rise in GLP-1 medications being used is leaving patients muscle-depleted and at risk of premature frailty.
Did you know that wihout appropriate intervention, GLP-1 medications can accelerate muscle loss equivalent to up to 20 years of age-related decline in just 12 months? It's genuinely concerning and not something to be taken lightly.
That's why ESSA is calling on governments to mandate referrals to Accredited Exercise Physiologists at the point of prescription, ensuring patients receive appropriate support to protect muscle health.
Here at the EP Studio, we are well-positioned to support people on GLP-1s. We're able to prescribe individualised programs that focus on strength training to help reduce the risk of age-related muscle and strength loss. All our practitioners are experts in strength training at any age and any stage.
Contact us (7123 2488 or [email protected]) to see how we can help!
ESSA CEO and Accredited Exercise Physiologist Katie Lyndon has been featured on page 3 of The Adelaide Advertiser, highlighting concerns that the rapid rise in GLP-1 weight loss medications is leaving some patients muscle-depleted and at risk of premature frailty.
ESSA is calling on governments to mandate referrals to Accredited Exercise Physiologists (AEPs) at the point of prescription, ensuring patients receive appropriate support to protect muscle health.
Today at the Activate Conference in Adelaide, ESSA is hosting a session: Exercise and weight loss in a world of lifestyle, stigma and pharmacology.
Presented by Dr Fiona Willer, AdvAPD, PhD, Dr Adelaide Boylan, Winthrop Professor Daniel Green and AEP Sara Slayman. Attendees will hear how, without appropriate intervention, these medications can accelerate muscle loss equivalent to up to 20 years of age-related decline in just 12 months.
Read The Advertiser article: https://bit.ly/4tah3jw
Read ESSA’s GLP-1 policy statement: https://bit.ly/4d87YBY